Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma

Respiratory Medicine

Volumn 107, Issue 2, 2013, Pages 180-195

  Corren, Jonathan ^a   Mansfield, Lyndon E ^b   Pertseva, Tetyana ^c   Blahzko, Viktor ^d   Kaiser, Kirsten ^e  

^a Allergy Medical Clinic   (United States)

^b Western Sky Medical Research   (United States)

^c Dnipropetrovsk State Medical Academy   (Ukraine)

^d Kharkiv City Clinical Hospital #13   (Ukraine)

^e SkyePharma   (Switzerland)

Author keywords

Asthma; Combination therapy; Fluticasone propionate; flutiform ; Formoterol fumarate; ICS LABA

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; CLINICAL LABORATORY; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MODERATE TO SEVERE ASTHMA; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SCHOOL CHILD; SINGLE DRUG DOSE; SINUSITIS; THORAX DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAL SIGN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872103379     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.10.025     Document Type: Article

References (50)

1. GINA Report Global strategy for asthma management and prevention 2009 http://www.ginasthma.com/ [accessed: January 2011]
2. D.M. Murphy, and P.M. O'Byrne Recent advances in the pathophysiology of asthma Chest 137 2010 1417 1426
3. M. Masoli, D. Fabian, S. Holt, and R. Beasley Global burden of asthma, a report for the global initiative for Asthma 2004 http://www.ginasthma.org [accessed: January 2011]
4. N. Ait-Khaled, D. Enarson, and J. Bousquet Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management Bull World Health Organ 79 2002 971 979
5. J.A. Van Noord, A.J.M. Schreurs, S.J.M. Mol, and P.G.H. Mulder Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma Thorax 54 1999 207 212
6. R.A. Pauwels, C.L. Lofdahl, D.S. Postma, A.E. Tattersfield, P. O'Byrne, P.J. Barnes, and A. Ullman Effect of inhaled formoterol and budesonide on exacerbations of asthma New Engl J Med 337 1997 1405 1411
7. C. Ward, M. Pais, R. Bish, D. Reid, B. Feltis, D. Johns, and E.H. Walters Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma Thorax 57 2002 309 316
8. R. Naedele-Risha, P. Dorinsky, and T.J. Craig Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting β-agonists with inhaled corticosteroids J Am Osteopath Assoc 101 2001 526 533
9. A.P. Greening, P.W. Ind, M. Northfield, and G. Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid Lancet 344 1994 219 224
10. A. Woolcock, B. Lundback, N. Ringdal, and L.A. Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Resp Crit Care 153 1997 1481 1488
11. P.M. O'Byrne, P.J. Barnes, R. Rodriguez-Roisin, E. Runnerstrom, T. Sandstrom, K. Svensson, and A. Tattersfield Low dose inhaled budesonide and formoterol in mild persistent asthma Am J Resp Crit Care 164 2001 1392 1397
12. M. Thomas, S. Kay, J. Pike, A. Williams, J.R. Carranza Rosenzweig, E.V. Hillyer, and D. Price The Asthma Control Test™ (ACT) as predictor of GINA guideline-defined asthma control: analysis of a multinational cross-section survey Prim Care Resp J 18 2009 41 49
13. P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Eur Resp J 19 2002 182 191
14. P.J. Barnes Scientific rationale for using a single inhaler for asthma control Eur Resp J 29 2007 587 595
15. M. Roth, J. Zhong, C.T. S'ng, and M. Tamm Effect of fluticasone and formoterol combination therapy on airway remodeling Eur Resp J 38 suppl. 55 2011 307s
16. 2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC) Eur Resp J 38 suppl. 55 2011 612s
17. E.D. Bateman, M. Britton, J. Carrillo, J. Almeida, and C. Wixon Salmeterol/fluticasone combination inhaler Clin Drug Investig 16 1998 193 201
18. M. Kavuru, J. Melamed, G. Gross, C. LaForce, K. House, B. Prillaman, L. Baitinger, A. Woodring, and T. Shah Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 105 2000 1108 1116
19. B. Stallberg, P. Olsson, L.A. Jorgensen, N. Lindarck, and T. Ekstrom Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing Int J Clin Pract 57 2003 656 661
20. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J.H. Clark, R.A. Pauwels, and S. Pedersen Can guideline-defined asthma control be achieved? Am J Resp Crit Care 170 2004 836 844
21. P.M. O'Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, T. Ekstrom, and E.D. Bateman Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma Am J Resp Crit Care 171 2005 129 136
22. G. Huchon, H. Magnussen, A. Chuchalin, L. Dymek, F. Bonnet Gonod, and J. Bousquet Lung function and asthma control with beclomethasone and formoterol in a single inhaler Resp Med 103 2009 41 49
23. C. Marceau, C. Lemiere, D. Berbiche, S. Perreault, and L. Blais Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma J Allergy Clin Immunol 118 2006 574 581
24. T.E. Delea, R.H. Stanford, M. Hagiwara, and D.A. Stempel Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs Curr Med Res Opin 24 2008 3435 3442
25. M.R. Partridge, T. van der Molen, S.E. Myrseth, and W.W. Busse Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study BMC Pulm Med 6 2006 13
26. S. Accordini, M. Bugiani, W. Arossa, S. Gerzeli, A. Marinoni, and M. Olivieri Poor control increases the economic cost of asthma. A multicentre population-based study Int Arch Allergy Immunol 141 2006 189 198
27. L. Cazzoletti, A. Marcon, C. Janson, A. Corsico, D. Jarvis, I. Pin, S. Accordini, E. Almar, and M. Bugiani Asthma control in Europe: a real-world evaluation based on an international population-based study J Allergy Clin Immunol 120 2007 1360 1367
28. P. Demoly, P. Paggiaro, V. Plaza, S.C. Bolge, H. Kannan, B. Sohier, and L. Adamek Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK Eur Resp Rev 18 2009 105 112
29. R.I. Ketchell, M.W. Jensen, D. Spina, and B.J. O'Connor Dose-related effects of formoterol on airway hyperresponsiveness to adenosine 5'-monophosphate and histamine Eur Resp J 19 2002 611 616
30. B. Luijk, R.D. Kempsford, A.M. Wright, P. Zanen, and J.W.J. Lammers Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction Eur Resp J 23 2004 559 564
31. N.P. Adams, J.C. Bestall, P. Jones, T.J. Lasserson, B. Griffiths, and C.J. Cates Fluticasone at different doses for chronic asthma in adults and children Cochrane Database Syst Rev 2008 CD003534
32. W.E. Berger The use of inhaled formoterol in the treatment of asthma Ann Allergy Asthma Immunol 97 2006 24 33
33. M.J. Politiek, M. Boorsma, and R. Aalbers Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction Eur Resp J 13 1999 988 992
34. M. Palmqvist, P. Arvidsson, O. Beckman, S. Peterson, and J. Lotvall Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers Pulm Pharmacol Therapeut 14 2001 29 34
35. J. Lotvall, and J. Ankerst Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients Resp Med 102 2008 449 456
36. AstraZeneca UK Ltd Symbicort turbohaler 100/6, inhalation powder. Summary of product characteristics 2010 http://www.medicines.org.uk [accessed: January 2011]
37. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2 National Asthma Education and Prevention Program (NAEPP) 1997 National Institute of Health; National Heart, Lung, and Blood Institute publication No. 97-4051
38. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
39. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, and A. Coates Standardisation of spirometry ATS/ERS task force: standardisation of lung function testing. Series No 2. Edited by Brusasco V, Crapo R and Viegi G. Eur Respir J 26 2005 319 338
40. G. Polgar, and V. Promdhat Pulmonary function testing in children: techniques and standards 1971 W. B. Sauncers Co Philadelphia
41. R.O. Crapo, A.H. Morris, and R.M. Gardner Reference spirometric values using techniques and equipment that meets ATS recommendations Am Rev Resp Dis 123 1981 659 664
42. Y.A. Hochberg sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
43. 2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over Health Tech Assess 12 iii-iv 2008 1 360
44. S. Dhillon, and G.M. Keating Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler Drugs 66 2006 1475 1483 discussion 1484-1485
45. C. Frois, E.Q. Wu, S. Ray, and G.L. Colice Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol Clin Ther 31 2009 2779 2803
46. K. McKeage, and S.J. Keam Salmeterol/fluticasone propionate: a review of its use in asthma Drugs 69 2009 1799 1828
47. G. Shapiro, W. Lumry, and J. Wolfe Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma Am J Respir Crit Care Med 161 2000 527 534
48. M. Noonan, L.J. Rosenwasser, and P. Martin Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial Drugs 66 2006 2235 2254
49. W.W. Busse, P. Chervinsky, J. Condemi, W.R. Lumry, R.L. Petty, S. Rennard, and R.G. Townley Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma J Allergy Clin Immunol 101 1998 457 463
50. G. Shapiro, L. Mendelson, M.J. Kraemer, M. Cruz-Rivera, K. Walton-Bowen, and J.A. Smith Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma J Allergy Clin Immunol 102 1998 789 796